GlassScriptPhysician profile
Carolina Goich
NPI 1124132063
$5,189.50
in general payments reported to CMS, 2019-2025
27 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $418 · 2023: $744 · 2024: $1,257 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,529.60 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,354.85 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $681.30 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.51 | 2021-2025 | Ofev, Jascayd |
| Pulmonx Corporation | $370.51 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $337.94 | 2021-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $307.99 | 2021-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $202.58 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $161.47 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $149.73 | 2021-2025 | |
| Verona Pharma, INC. | $146.97 | 2025 | Ohtuvayre |
| Pfizer INC. | $118.89 | 2021-2025 | |
| Insmed, INC. | $111.62 | 2021-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $94.50 | 2021-2024 | Winrevair |
| Mylan Specialty L.P. | $74.36 | 2021-2024 | Yupelri |
| Philips North America LLC | $71.64 | 2023-2025 | Vest Therapy Und |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $65.98 | 2021 | |
| Nabriva Therapeutics, Plc | $64.86 | 2021 | |
| Baxter Healthcare | $43.98 | 2023 | Hillrom - Life 2000 Ventilation System |
| Actelion Pharmaceuticals US, INC. | $43.14 | 2021 | |
| Amgen INC. | $39.11 | 2024 | Tezspire |
| Electromed, INC. | $36.69 | 2023-2024 | Smartvest |
| Inogen, INC. | $27.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $23.99 | 2021 | |
| Inspire Medical Systems, INC. | $22.84 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $19.23 | 2024 | Sunosi |
| United Therapeutics Corporation | $19.15 | 2021 | |
| Harmony Biosciences LLC | $18.67 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolina Goich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.